GrayMatters Health (GMH) develops digital self-neuromodulation therapeutics for mental disorders to help patients regain agency over their emotion regulation. GMH offers Prism, a non-invasive adjunct therapeutic that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers. The company's first product candidate, Prism for PTSD, is undergoing clinical investigation in five sites across the United States and Israel, to demonstrate its efficacy and safety as an adjunct to standard PTSD treatments.

GrayMatters Health (גריי מאטרס הלת' בע~מ)

GrayMatters Health (גריי מאטרס הלת' בע~מ)